aTyr Pharma, Inc. (LIFE): Price and Financial Metrics

aTyr Pharma, Inc. (LIFE): $1.95

0.05 (-2.50%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add LIFE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#320 of 365

in industry

LIFE Price/Volume Stats

Current price $1.95 52-week high $2.70
Prev. close $2.00 52-week low $1.08
Day low $1.89 Volume 726,100
Day high $2.05 Avg. volume 554,402
50-day MA $1.79 Dividend yield N/A
200-day MA $1.66 Market Cap 132.11M

LIFE Stock Price Chart Interactive Chart >

LIFE POWR Grades

  • Sentiment is the dimension where LIFE ranks best; there it ranks ahead of 98.82% of US stocks.
  • The strongest trend for LIFE is in Growth, which has been heading down over the past 26 weeks.
  • LIFE ranks lowest in Quality; there it ranks in the 11th percentile.

LIFE Stock Summary

  • Of note is the ratio of ATYR PHARMA INC's sales and general administrative expense to its total operating expenses; only 9.19% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 75.91%, ATYR PHARMA INC's debt growth rate surpasses 89.95% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for LIFE comes in at -67.11% -- higher than that of just 6.26% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ATYR PHARMA INC, a group of peers worth examining would be MGNX, IKNA, TCRX, SYBX, and SYRS.
  • Visit LIFE's SEC page to see the company's official filings. To visit the company's web site, go to www.atyrpharma.com.

LIFE Valuation Summary

  • In comparison to the median Healthcare stock, LIFE's price/earnings ratio is 106.52% lower, now standing at -1.9.
  • Over the past 105 months, LIFE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for LIFE.

Stock Date P/S P/B P/E EV/EBIT
LIFE 2023-12-29 7.7 0.8 -1.9 -2.0
LIFE 2023-12-28 8.0 0.9 -2.0 -2.0
LIFE 2023-12-27 8.0 0.9 -2.0 -2.0
LIFE 2023-12-26 8.0 0.9 -2.0 -2.0
LIFE 2023-12-22 7.4 0.8 -1.8 -1.9
LIFE 2023-12-21 7.3 0.8 -1.8 -1.9

LIFE Growth Metrics

    The 2 year revenue growth rate now stands at -100%.
  • Its year over year cash and equivalents growth rate is now at -33.87%.
  • Its 3 year price growth rate is now at -50.09%.
LIFE's revenue has moved down $422,000 over the prior 33 months.

The table below shows LIFE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0 -39.603 -46.376
2022-06-30 0 -38.792 -40.799
2022-03-31 0 -37.367 -38.77
2021-12-31 0 -33.075 -33.768
2021-09-30 2.053 -30.39 -30.141
2021-06-30 2.201 -24.475 -29.073

LIFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LIFE has a Quality Grade of C, ranking ahead of 43.43% of graded US stocks.
  • LIFE's asset turnover comes in at 0.048 -- ranking 321st of 682 Pharmaceutical Products stocks.
  • CBIO, ASMB, and CLSD are the stocks whose asset turnover ratios are most correlated with LIFE.

The table below shows LIFE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.048 1 -0.965
2021-03-31 0.052 1 -0.976
2020-12-31 0.229 1 -0.842
2020-09-30 0.190 1 -0.815
2020-06-30 0.189 1 -0.709
2020-03-31 0.185 1 -0.587

LIFE Price Target

For more insight on analysts targets of LIFE, see our LIFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.40 Average Broker Recommendation 1.43 (Moderate Buy)

aTyr Pharma, Inc. (LIFE) Company Bio


aTyr Pharma, Inc. is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. aTyr research and development focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Over the last ten years, the company has developed an international portfolio of intellectual property, including 20 human tRNA synthetases and over 300 protein compositions patented. Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. aTyr’s headquarters is located in San Diego, California and the company employs 42 people.


LIFE Latest News Stream


Event/Time News Detail
Loading, please wait...

LIFE Latest Social Stream


Loading social stream, please wait...

View Full LIFE Social Stream

Latest LIFE News From Around the Web

Below are the latest news stories about ATYR PHARMA INC that investors may wish to consider to help them evaluate LIFE as an investment opportunity.

aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With Losses

Insiders who bought US$501.6k worth of aTyr Pharma, Inc.'s ( NASDAQ:LIFE ) stock at an average buy price of US$2.23...

Yahoo | November 13, 2023

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2

Yahoo | November 13, 2023

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing. Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of firs

Yahoo | November 9, 2023

aTyr Pharma to Present at November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023. Details of the presentations appear below: Conference: Jefferies London Healthcare C

Yahoo | November 1, 2023

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD

Multiple centers in the U.S. are open for enrollmentSAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study. The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead the

Yahoo | October 31, 2023

Read More 'LIFE' Stories Here

LIFE Price Returns

1-mo 2.63%
3-mo 38.30%
6-mo 23.42%
1-year -7.14%
3-year -55.58%
5-year -74.68%
YTD 38.30%
2023 -35.62%
2022 -70.68%
2021 92.53%
2020 -6.95%
2019 -39.95%

Continue Researching LIFE

Want to see what other sources are saying about aTYR PHARMA INC's financials and stock price? Try the links below:

aTYR PHARMA INC (LIFE) Stock Price | Nasdaq
aTYR PHARMA INC (LIFE) Stock Quote, History and News - Yahoo Finance
aTYR PHARMA INC (LIFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!